EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
16.66
0.00 (0.00%)
Pre-market: 16.60 -0.06 (-0.36%)
Jul 22, 9:12AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 9.53 - 17.74
Open     -
Vol / Avg. 100.00/1.11M
Mkt cap 1.38B
P/E     -
Div/yield     -
EPS -0.75
Shares 82.84M
Beta 1.18
Inst. own 81%
Jul 24, 2014
EXACT Sciences Corporation Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
Jul 22, 2014
Q2 2014 Exact Sciences Corp Earnings Call - 10:00AM EDT - Add to calendar
Jul 22, 2014
Q2 2014 EXACT Sciences Corporation Earnings Release - 10:00AM EDT - Add to calendar
Jun 25, 2014
EXACT Sciences Corporation at JMP Securities Healthcare Conference
Jun 12, 2014
Exact Sciences Corp at Goldman Sachs Healthcare Conference
Jun 11, 2014
EXACT Sciences Corporation at William Blair & Company LLC Growth Stock Conference
Jun 3, 2014
EXACT Sciences Corporation at Jefferies Global Healthcare Conference
May 14, 2014
EXACT Sciences Corporation at Bank of America Merrill Lynch Health Care Conference
May 6, 2014
EXACT Sciences Corporation at Robert W. Baird & Co. Inc Growth Stock Conference
May 1, 2014
Q1 2014 EXACT Sciences Corporation Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -5478.57% -1122.44%
Operating margin -5502.72% -1128.40%
EBITD margin - -1094.18%
Return on average assets -46.02% -35.95%
Return on average equity -50.26% -39.77%
Employees 102 -
CDP Score - -

Address

441 Charmany Drive
MADISON, WI 53719
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company�s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company�s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The Company�s Cologuard test includes methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 65
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 52
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 63
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 59
Bio & Compensation  - Reuters